AUSTIN, Texas, Aug. 21 /PRNewswire-FirstCall/ -- Introgen Therapeutics announced today that molecular and clinical biomarker data that can predict ADVEXIN therapeutic efficacy was selected for presentation at the 2006 Annual Meeting of the American Head and Neck Society. Analyses of predictive biomarkers defined subset populations of head and neck cancer patients that may achieve the most benefit from ADVEXIN treatment. Dr. Robert E. Sobol, Introgen’s senior vice president of Medical and Scientific Affairs, presented the data yesterday during the conference in Chicago.
Dr. Sobol discussed the identification of a set of prognostic indicators associated with high response rates and increased survival in Phase 2 clinical trials of Introgen’s ADVEXIN therapy in patients with recurrent squamous cell carcinoma of the head and neck. Biomarkers are tests or measurements that predict response to treatment. Molecular biomarkers include measurements of genetic markers or molecular pathways while clinical biomarkers refer to clinical history or clinical measurements. Application of these biomarkers can predict the patients who are most likely to respond to ADVEXIN treatment. This information can be utilized to guide ADVEXIN treatment of cancer patients and to support approval of ADVEXIN for these patients by regulatory agencies.
The American Head and Neck Society (AHNS) Annual Meeting is the pre- eminent location for head and neck specialists to present their clinical research, to receive updates on the latest treatment techniques, and to interact with colleagues within the specialty. The conference attendees included approximately 750 physicians and researchers, including practicing surgeons, clinical investigators, immunologists and molecular and cellular biologists discussing developments for the prevention and treatment of head and neck cancer.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be “forward-looking” statements, including those relating to Introgen’s future success with its clinical development program for ADVEXIN in the treatment of head and neck cancer. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: http://www.introgen.com .
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke@introgen.com
Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc., +1-512-708 9310Ext. 322, or c.burke@introgen.com
Web site: http://www.introgen.com/
